MSDC-0602 potassium | CAS#1314533-27-1

MedKoo Cat#: 534800 | Name: MSDC-0602 potassium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MSDC-0602 is an insulin sensitizer potentially for the treatment of diabetes (metabolic modulator).

Chemical Structure

MSDC-0602 potassium

CAS#1314533-27-1 (potassium)

Theoretical Analysis

MedKoo Cat#: 534800

Name: MSDC-0602 potassium

CAS#: 1314533-27-1 (potassium)

Chemical Formula: C19H16KNO5S

Exact Mass: 409.0386

Molecular Weight: 409.50

Elemental Analysis: C, 55.73; H, 3.94; K, 9.55; N, 3.42; O, 19.53; S, 7.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1133819-87-0 (free base) 1314533-26-0 (sodium) 1314533-27-1 (potassium)

Synonym

MSDC-0602 potassium; MSDC-0602; MSDC 0602; MSDC0602; AZEMIGLITAZONE POTASSIUM

IUPAC/Chemical Name

2,4-Thiazolidinedione, 5-((4-(2-(3-methoxyphenyl)-2-oxoethoxy)phenyl)methyl)-, potassium salt (1:1)

InChi Key

PQCFIIIBRQVVGW-UHFFFAOYSA-M

InChi Code

InChI=1S/C19H17NO5S.K/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17;/h2-8,10,17H,9,11H2,1H3,(H,20,22,23);/q;+1/p-1

SMILES Code

O=C([N-]1)SC(CC2=CC=C(OCC(C3=CC=CC(OC)=C3)=O)C=C2)C1=O.[K+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 409.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2017 May;65(5):1543-1556. doi: 10.1002/hep.29025. Epub 2017 Mar 30. PMID: 28027586; PMCID: PMC5397348. 2: Colca JR, McDonald WG, Adams WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. Expert Opin Investig Drugs. 2018 Jul;27(7):631-636. doi: 10.1080/13543784.2018.1494153. Epub 2018 Jul 17. PMID: 29950116. 3: Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J Bone Miner Res. 2015 Mar;30(3):481-8. doi: 10.1002/jbmr.2364. PMID: 25257948; PMCID: PMC4472363. 4: Vigueira PA, McCommis KS, Hodges WT, Schweitzer GG, Cole SL, Oonthonpan L, Taylor EB, McDonald WG, Kletzien RF, Colca JR, Finck BN. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism. Exp Physiol. 2017 Aug 1;102(8):985-999. doi: 10.1113/EP086380. Epub 2017 Jul 10. PMID: 28597936; PMCID: PMC5667918. 5: Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, Qi N, McDonald WG, Colca JR, Kletzien RF, Finck BN. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. doi: 10.1074/jbc.M112.363960. Epub 2012 May 23. PMID: 22621923; PMCID: PMC3390629. 6: Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism. 2020 Mar 6:154203. doi: 10.1016/j.metabol.2020.154203. Epub ahead of print. PMID: 32151660. 7: Colca JR, McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, Wolfe CL, Wheeler JS, Coulter KR, Kilkuskie PM, Gracheva E, Korshunova Y, Trusgnich M, Karr R, Wiley SE, Divakaruni AS, Murphy AN, Vigueira PA, Finck BN, Kletzien RF. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. 2013 May 15;8(5):e61551. doi: 10.1371/journal.pone.0061551. PMID: 23690925; PMCID: PMC3655167.

View History

Istaroxime mesylate

MedKoo CAT#: 563725

CAS#: Unknow